<DOC>
	<DOCNO>NCT00199953</DOCNO>
	<brief_summary>Objectives study : - To quantitatively evaluate relationship extraesophageal manifestation gastroesophageal reflux ( EER ) postnasal drainage ( PND ) group patient without radiographic endoscopic evidence sinonasal inflammatory disease . - To assess efficacy BID proton pump inhibitor ( PPI ) management patient symptomatic postnasal drainage .</brief_summary>
	<brief_title>Post-nasal Drainage Extraesophageal Manifestation Reflux</brief_title>
	<detailed_description>Gastroesophageal reflux disease ( GERD ) common disorder esophagus , affect 7-10 % U.S. population . Characteristic symptom include heartburn , chest pain , indigestion . EER denote gastroesophageal refluxate reach structure upper esophageal sphincter . EER implicate pathogenesis several otolaryngologic disorder chronic posterior laryngitis , laryngeal contact ulcer granuloma , paroxysmal laryngospasm , vocal cord nodule , Reinke 's edema , subglottic laryngotracheal stenosis , globus pharyngeus , laryngeal hypopharyngeal carcinoma . In addition , EER associate disorder low upper respiratory tract chronic sinonasal inflammation . Patients EER rarely complain common symptom GERD , heartburn . Often present symptom involve larynx pharynx , include throat-clearing , globus pharyngeus , postnasal drainage . These symptom may present due direct irritation nasal epithelium gastric refluxate and/or neurogenic inflammatory process mediate autonomic nervous system . Specific Aims : - Specific Aim 1 : To establish relation ship EER PND patient without sinonasal inflammatory disease . - Hypothesis 1 : In patient without radiographic endoscopic evidence sinonasal inflammatory disease , PND symptom EER . - Method 1 : We test hypothesis utilizing 2-site 24-hour pH probe test symptomatic patient group compare previously test age sex-matched control group . - Specific Aim 2 : To establish efficacy PPI management PND . - Hypothesis 2 : Patients chief complaint PND sinonasal inflammatory disease improve 3-month PPI treatment Rabeprazole 20 mg twice day . - Method 2 : A group patient chief complaint postnasal drainage , without radiographic endoscopic evidence sinonasal inflammatory disease enter prospective placebo-controlled trial utilize BID PPIs 3-month period . primary outcome measure : 1 ) Visual analog Scales , assess severity frequency PND day 0 90 treatment 2 ) A quantitative color analysis laryngeal erythema , utilize videolaryngoscopy day 0 90 treatment .</detailed_description>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Age &gt; 18 &lt; 70 ; PND chief complaint ; No know acute chronic sinus disease ; Nonsmokers ; Subjects history esophageal gastric surgery Subjects history allergic disease Women non pregnant . Age , 18 &gt; 70 ; No PND chief complaint Al ; ergic disease acute chronic sinus disease ; Smokers ; Pregnant woman ; Subjects history esophageal gastric surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Postnasal drainage</keyword>
	<keyword>Extraesophageal reflux</keyword>
</DOC>